EWTX recently disclosed that its cash, cash equivalents, and marketable securities totaled approximately $436.4 million as of the end of March. The company's CEO highlighted substantial advancements in their skeletal and cardiac muscle initiatives. Notably, EWTX revealed encouraging top-line outcomes from the CIRRUS-HCM study and completed a $200 million offering to support both immediate and future objectives.
These objectives encompass preparing for potential U.S. approval of sevasemten in Becker's muscular dystrophy, advancing a Phase 3 trial for Duchenne muscular dystrophy, and pursuing a Phase 3 program in hypertrophic cardiomyopathy (HCM). The company also continues to focus on its active research and development efforts. EWTX anticipates achieving several significant milestones in its sevasemten and EDG-7500 programs throughout the year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Edgewise Therapeutics Inc (EWTX, Financial) is $40.78 with a high estimate of $52.00 and a low estimate of $14.00. The average target implies an upside of 180.84% from the current price of $14.52. More detailed estimate data can be found on the Edgewise Therapeutics Inc (EWTX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Edgewise Therapeutics Inc's (EWTX, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
